Ankit K. Desai

发表

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

A. Rosenberg, J. Sleasman, P. Kishnani, 2020, Frontiers in Immunology.

Pulmonary outcome measures in long‐term survivors of infantile Pompe disease on enzyme replacement therapy: A case series

M. ElMallah, R. Kravitz, P. Kishnani, 2020, Pediatric pulmonology.

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease

S. Packman, O. Abdul-Rahman, P. Tanpaiboon, 2018, Genetics in Medicine.

Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

P. Kishnani, L. Case, J. Coats, 2017, Molecular genetics and metabolism.

High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.

A. Rosenberg, P. Kishnani, Ankit K. Desai, 2017, Molecular genetics and metabolism.

A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation

P. Kishnani, R. Spiegel, S. Curelaru, 2022, Molecular genetics and metabolism reports.

A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease

P. Kishnani, Fuad M. Kiblawi, D. Myridakis, 2020, Frontiers in Immunology.

Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy

D. Bali, P. Kishnani, Ankit K. Desai, 2019, Molecular genetics and metabolism reports.

Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.

P. Kishnani, Heidi Cope, Stephanie M Dearmey, 2017, Molecular genetics and metabolism.

Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease.

D. Bali, Sang-oh Han, D. Koeberl, 2019, Molecular genetics and metabolism.

Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.

A. Rosenberg, P. Kishnani, Ankit K. Desai, 2019, Annals of translational medicine.

The emerging phenotype of late-onset Pompe disease: A systematic literature review.

L. Hobson‐Webb, P. Kishnani, L. Case, 2017, Molecular genetics and metabolism.

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via Newborn Screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction

W. Craigen, P. Tanpaiboon, R. Hopkin, 2021, Genetics in Medicine.

Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.

O. Abdul-Rahman, P. Tanpaiboon, A. Rosenberg, 2017, JCI insight.

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

A. D. De Groot, P. Kishnani, W. Martin, 2021, Frontiers in Immunology.

Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome

P. Kishnani, K. Lindstrom, L. Pollard, 2020, Frontiers in Immunology.

Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease.

E. Bossen, P. Kishnani, A. Buckley, 2023, Journal of neuropathology and experimental neurology.

Successful AAV8 readministration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease

W. Jeck, Jeong-A Lim, T. Tedder, 2023, The journal of gene medicine.

The emerging phenotype of late-onset Pompe disease: A systematic literature review.

L. Hobson‐Webb, P. Kishnani, L. Case, 2017, Molecular genetics and metabolism.

Cross-reactive immunologic material positive infantile Ρompe disease: Characterization of immune responses in patient treated with enzyme replacement therapy

P. Kishnani, Ankit K. Desai, Z. Kazi, 2016 .

Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease

Ankit K. Desai, Priya S. Kishnani, Amy S. Rosenberg, 2024, Frontiers in immunology.

Pediatric Pulmonology

R. Kravitz, Stephanie M Dearmey, Ankit K. Desai, 2020 .

Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy

Y. Chien, W. Hwu, Hui-An Chen, 2024, Frontiers in immunology.

Optimizing clinical outcomes: The journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation

Ankit K. Desai, Laura E. Case, Priya S. Kishnani, 2024, Molecular genetics and metabolism reports.

An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation

Ankit K. Desai, Raymond Y. Wang, Priya S. Kishnani, 2024, Frontiers in Immunology.

The potential impact of timing of IVIG administration on safety and efficacy of rituximab administration in the setting of immune tolerance induction for patients with Pompe disease.

A. Rosenberg, P. Kishnani, Ankit K. Desai, 2020, Clinical immunology.

Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy

P. Kishnani, Ankit K. Desai, E. Vucko, 2023, Molecular genetics and metabolism reports.